Transplantation between red cell-disparate donor and recipient is feasible with minimal increase in the risk of transplantation if consideration is given to the immunohematological consequences of the transplant. The risks of immediate and delayed hemolysis must be managed. Some recipients will experience a delay in the recovery of red blood cells. Bone Marrow Transplantation (2001) 28, 315-321.
antibody(s) in the donor or recipient not of a particular blood group, and the possibility of severe hemolysis with infusion of ABO incompatible blood. It is more likely that sibling pairs will not match for ABO antigens compared to other red cell antigens. However, red cell antigens of other systems can also present a challenge for management of the transplant patient if antibodies exist either in the donor or recipient and red cell incompatibility encompasses ABO, Rh, and other red cell antigen systems. 4, 5 Basic immunohematology principles apply to the infusion of red cell incompatible HSC components -processing of the component or preparation of the recipient may be necessary to prevent hemolysis of donor or recipient red blood cells as a result of the infusion of incompatible red blood cells or plasma contained within the HSC component. [2] [3] [4] [5] [6] [7] [8] This, of course, applies only to those antigen systems capable of causing hemolytic transfusion reactions at body temperature. However, in contrast to blood transfusion, the risk of hemolysis occurs not only at the time of infusion but can also can occur later if viable lymphocytes in the HSC component produce isoagglutinins directed against recipient red cell antigens.
Red cell incompatibility is classified according to whether donor isoagglutinins, isoantigens, or both are incompatible with those of the recipient. Major incompatibility occurs when patients have antibodies directed against donor red blood cell antigens (eg A donor, O recipient); minor incompatibility occurs when donor plasma contains antibodies directed against patient red cells (eg O donor, A recipient). For some transplants, bidirectional incompatibility may be present (eg A donor, B recipient).
The immediate risk of major incompatible bone marrow transplantation is the risk of clinically significant hemolysis of large quantities of red cells contained in the HSC inoculum, a risk that is much lower for recipients of PBSC collected by apheresis because of the lower volume of red blood cells in these components (usually about 2-5% of the component volume) compared to marrow components (usually about 25-35% of the component volume). The risk of clinically relevant hemolysis is reduced by removal of red cells from the HSC component using any of a variety of sedimentation techniques or reduction of isoagglutinin titer for the recipient by plasma exchange. Major red cell incompatible HSC recipients may also experience delayed red cell recovery after transplantation because of persistent host isoagglutinins that suppress red cell hematopoiesis.
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For a small proportion of patients, host isoagglutinins and red cell transfusion requirement may persist for years before complete resolution.
In contrast, patients receiving minor incompatible transplants face a risk of immediate hemolysis from the infusion of incompatible plasma contained in the HSC component. The risk of hemolysis of recipient red cells depends upon the volume and titer of isoagglutinin contained in the HSC component. Of much greater clinical import, these patients may also experience delayed but life-threatening hemolysis mediated by viable donor lymphocytes carried in the HSC component. [14] [15] [16] These viable 'passenger lymphocytes' are capable of transiently producing adequate levels of isoagglutinins to result in hemolysis of recipient red blood cells 7-14 days after transplantation. This delayed hemolysis after minor ABO-incompatible HSC transplants can be severe and fatal, and is more likely to occur in group A recipients with a group O donor. This hemolysis may also involve group O red cells used in transfusion support, 15 possibly through absorption of group A or B antigens on to the cell membrane of the group O cells. 16 The incidence of hemolysis after minor ABO-incompatible transplantation is not established and may relate to the post-transplant immunosuppression used to suppress GVHD, 15 occurring rarely, if ever, if methotrexate is used in the GVHD prophylactic regimen. It is also not clear if manipulation of the HSC component before infusion, such as T or B cell depletion, will alter the risk of this complication. Authors of several recently published case reports of hemolysis occurring after minor or bidirectional ABO-incompatible PBSC transplantation suggest that PBSC recipients are at greater risk of this complication than are marrow recipients, and that both the frequency of occurrence and severity of the hemolysis may be explained by the much greater number of lymphocytes contained in a PBSC inoculum. [17] [18] [19] [20] [21] However, an increased risk of delayed hemolysis after PBSC transplantation has not been observed by this author for a large series of patients, 22 but these patients received methotrexate or similar medication as part of the GVHD regimen.
Effect of red cell incompatibility on transplant outcome
Red cell incompatibility has not been associated with engraftment failure or risk of acute or chronic GVHD. In subset analysis, one group associated major red cell incompatibility with higher peri-transplant mortality resulting from organ toxicity and sepsis for patients with AML and MDS. 23 These investigators subsequently suggested the increased risk of death for these patients may have resulted from the transfusion practice of not reducing the plasma contained in ABO-incompatible platelet components. 24 (This group and others have proposed the infusion of ABOincompatible plasma containing small amounts of isoantigens to reduce recipient isoagglutinins suppressing donor erythropoiesis.) 12, 25 Many, if not most, of the red cells not subject to intravascular hemolysis because of low levels of isoagglutinin binding are removed by the extravascular reticuloendothelial system and it is conceivable that a deleterious effect could result from this phenomenon.
Management of red cell incompatibility
All donors and recipients involved in HSC transplantation must be typed for ABO group and Rh. Antibody screen must also be performed for both the donor and recipient to identify non-ABO red cell antibodies that could result in red cell hemolysis. A red cell cross-match between the donor and recipient should be performed if the pair is not already identified as being ABO-incompatible. The antibody screen and red cell cross-match must be performed within 30 days of donation, and should be repeated, in accordance with red cell transfusion guidelines, 26 within 3 days before HSC infusion, especially if the recipient is receiving transfusions and could become immunized to non-ABO red cell antigens that the donor expresses.
Major red cell incompatibility
The risk of clinically relevant hemolysis is greater for recipients of bone marrow that for other sources of HSC because of the large quantity of red cells contained within the HSC component. Major incompatible HSC components can be infused if the red cells are removed from the component or if recipient isoagglutinins are present at low titer naturally or after reduction by plasma exchange.
The clearance of incompatible red blood cells from the circulation is related to the volume of red cells infused and the titer of the antibody present. Small quantities of red cells will be removed from the circulation by hemolysis with a t . of a few minutes. These red cells will absorb antibodies from the plasma resulting in a decrease in the isoagglutinin titer. Thus, infusion of large quantities of red cells in patients with low isoagglutinin titers will result in decreasing quantities of antibody molecules bound to the red cells and a prolongation of red cell clearance (t . ) to days or weeks. Patients with low isoagglutinin titers (IgM or IgG, 1:16 or less in this author's experience) can generally safely receive unmodified bone marrow ( Figure 1 ). Immediate hemolysis of red cells will be limited to a small quantity of red cells infused and the remainder of the red cells will be removed over a period of days. Disseminated intravascular coagulopathy (DIC) or renal failure, which may occur after incompatible red cell infusion, has not been attributed to this practice. However, it is difficult to distinguish hemolytic transfusion reaction from fat embolism and the transplant service must be prepared to manage the patient, even one with low antibody titers, who is reacting to the infusion of unmodified bone marrow. In this situation, red cell and plasma depletion removes both red cells and bone marrow fat.
The immediate risk of hemolysis resulting from the infusion of bone marrow containing a large quantity of incompatible red cells can also be avoided by removal of the incompatible red cells using any of a variety of sedimentation techniques. 7, [27] [28] [29] The sedimentation of red cells can be enhanced by the addition of macromolecules such as hydroxyethylstarch to the component. 30 Any of the apheresis devices can be used to separate red blood cells from the bone marrow component. 7, [27] [28] [29] The processed component usually contains 5-20 ml of red blood cells. The recov- 
ery of nucleated cells and of mononuclear cell populations including CD34
+ and CD3 + cells depends upon the apheresis technique being used: modern apheresis techniques result in the recovery of only about 60% of nucleated cells containing 80-100% of the mononuclear cell populations of interest (eg granulocytes are relatively depleted). A deleterious effect of marrow processing for red blood cell depletion on transplant outcome has not been reported for either allogeneic or autologous HSC transplantation, if HSC quantity and function are properly preserved.
In situations where cell dose may be important to transplant outcome, 31 the minimal cell losses of red cell depletion can be avoided by isoagglutinin reduction of the recipient. Isoagglutinin titers can be depleted by large volume plasma exchange (10 liters) performed on the day of infusion and on additional, preceding days for patients with higher titers. Up to 4 days of exchange may be required (1 day for patients with isoagglutinin titers of 1:32-1:128, 2 days for titers of 1:256-1:512, 3 days for a titer of 1:1024, and 4 days for a titer of 1:2048. Both IgM and IgG isoagglutinin titers should be 1:16 or less on the day of HSC infusion.) Plasma exchange is unlikely to be adequate for the management of patients with titers Ͼ1:2048 and these patients should receive red cell-depleted components. Donor ABO-type plasma (or group AB plasma) is used for at least half the replacement fluid to avoid depletion of clotting factors and other plasma proteins. Large volume plasma exchange is expensive and toxic with frequent allergic and febrile reactions even after administration of pre-medications and despite the immune suppression resulting from the conditioning regimen used for allogeneic transplantation. Although never observed by this author, Bone Marrow Transplantation delayed hemolysis of the infused red cells may occur for patients who are prepared for the infusion by isoagglutinin reduction if recipient isoagglutinins rebound after the apheresis procedures. 32 PBSC collected and marrow components processed by apheresis technology usually contain less than 10-15 ml of red cells and present little risk of clinically severe hemolysis on infusion. Secondary processing of PBSC components is, generally, not required, although all transplant programs must set criteria for the red cell content of the HSC component(s) collected from red cell-incompatible donors.
The other consequence of major ABO-incompatible transplantation is a delay in recovery of red cells until loss of isoagglutinins directed against donor red cell antigens. Patients receiving major or bi-directional incompatible red cell components require greater numbers of red cell transfusions and achieve transfusion independence later than comparable patients receiving red cell compatible or minor incompatible components. Pure red cell aplasia lasting months to years can occur in this setting. [9] [10] [11] [12] [13] The expression of ABO antigens occurs about the time of hemoglobinization. 33 However, it is very unlikely that major elevations in bilirubin or LDH occurring before red cell engraftment are related to intra-medullary hemolysis in this setting. In one case report, the authors attributed several episodes of hemolysis to persistent host isoagglutinins directed against donor red cells. 34 The positive anti-globulin tests described and the ability to elute host isoagglutinins from red cells of donor type required that erythropoiesis was robust enough to produce a significant proportion of donor-derived red blood cells, which conflicts with the red cell aplasia reported by most authors. Sniecinski et al 35 similarly reported delayed hemolysis for five patients, occurring at a median of 65 days after transplantation. Allogeneic transplant recipients experience post-transplant non-immunologic hemolytic events that mimic hemolytic-transfusion reactions, such as microangiopathic hemolysis, that are probably much more likely to account for significant hemolysis in the months after allogeneic transplantation. Furthermore, unexplained sudden drops of hemoglobin values commonly occur late after allogeneic (or autologous) transplantation for ABO-matched as well as mismatched recipients.
Patients with delayed loss of recipient isoagglutinins may require years of transfusion support (Figure 2 ). This can be a frustrating experience for the patient and medical staff, although eventually, the patient will become transfusion independent. The drop in isoagglutinin titers follows an exponential curve and usually occurs over 6-8 weeks after transplantation. 22 The drop will be faster after unrelated donor transplantation. 36 Attempts to hasten red cell recovery have involved plasmapheresis or immunoadsorption in an attempt to reduce isoagglutinin titers, 10, 12 erythropoietin to enhance red cell production, 10, 37, 38 and immunosuppression with glucocorticoids or anti-thymocyte globulin. 39 The value of these maneuvers is open to question. Plasmapheresis is most effective in removing IgM antibodies and has poor efficiency in removal of IgG antibodies, which are distributed throughout the intravascular and extravascular fluid compartments of the body. If the isoagglutinin is of high avidity, it is unlikely that the titer can be reduced to low enough levels to allow erythropoiesis to occur, even with an aggressive plasmapheresis approach. Benjamin et al 12 suggested that use of fresh frozen plasma containing small amounts of soluble isoantigens is effective when plasmaphereis using plasma protein fractions is not. Infusion of donor-type fresh-frozen plasma may be similarly effective. 25 Reports of erythropoietin response are limited to patients whose isoagglutinin titers had fallen to undetectable levels and is probably of little value for other patients with detectable levels. Treatment with B cell-directed antibodies such as rituximab may be an approach with low risk of toxicity, but case reports have not yet been published. Infusion of additional donor T cells to enhance the graftversus-host response can also be effective, 40 but carries the risk of uncontrollable GVHD, which clearly outweighs the risks and cost of transfusion support for most patients.
Minor red cell incompatibility
The depletion of plasma from minor ABO-incompatible components is easily performed by centrifugation and concentration of the cells, and should be considered for components with large amounts of plasma from high-titer donors (Figure 1 ). This approach is probably routinely performed by most centers performing bone marrow transplantation. This author has not observed any deleterious consequences of directly infusing unmodified PBSC components. The risk of this practice is related to the volume of plasma, the isoagglutinin titer of the donor, and the body size of the recipient, and patient management should be individualized if plasma depletion is not routinely performed as suggested in this algorithm.
Massive hemolysis occurring as a delayed consequence of infusion of viable donor lymphocytes ('passenger lymphocytes') may result in patient death after minor ABOincompatible transplantation. The incidence of and risk factors for delayed hemolysis for recipients of minor ABOincompatible cells are not defined. Donor immunity is not maintained after transplantation and this phenomenon is transient, probably limited to the first few weeks after transplantation. When hemolysis occurs, it is brisk and severe, frequently leading to patient death unless promptly recognized and treated. Most transplant programs will avoid transfusion of recipient-type red blood cells after transplantation. Transfusion of group O cells will dilute the quantity of recipient red cells and, presumably, reduce the risk of extensive hemolysis. The number of red cells hemolyzed, however, can exceed the quantity of recipient-type red cells by a considerable proportion. Why transfused red blood cells of group O hemolyze is not clear but could be a result of passive adsorption of ABO antigens on to the group O cells. Some transplant programs use red cell exchange to further reduce the quantity of incompatible red cells in the recipient. 15 A red cell exchange will reduce the quantity of recipient-type red cells by about 50%. There is no evidence that this reduces the risk of or the severity of hemolysis and routine use of this approach is not required if adequate immunosuppression is used after transplantation.
Gajewski et al 15 suggested that post-transplant immunosuppressive regimens containing methotrexate reduces the risk of delayed hemolysis mediated by viable lymphocytes contained within the HSC inoculum, and this may explain the suggestion that the risk of hemolysis is higher after transplantation of T cell-depleted marrows without the post transplant use of anti-metabolite medications. 41 The case reports of delayed hemolysis after PBSC transplantation involved patients who received regimens without metho-trexate or for whom some doses of this drug were withheld. [18] [19] [20] [21] However, the incidence of hemolysis after transplantation in the absence of methotrexate is also not defined. Not all patients will experience delayed hemolysis and the risk factors could include both donor and recipient factors. Suggestions of a relationship between dose of lymphocytes and the incidence or severity of this complication can only be speculative in the absence of a larger series of patients experiencing hemolysis. In this author's series of patients undergoing red cell incompatible PBSC transplantation, most patients received two drug prophylactic regimens that included methotrexate or similar medication after transplantation. 22 Methotrexate (and other agents such as mycophenylate mofitil) is an anti-proliferative agent that may suppress the proliferation of donor lymphocytes carried in the HSC inoculum. 42 A greater proportion of patients will develop laboratory evidence of isoagglutinin production than will show overt evidence of hemolysis. Hows et al 14 reported that 15 of 18 patients showed evidence of red cell antibody production directed against recipient red cells 1 to 3 weeks after transplantation, but only three of 21 patients experienced clinically significant hemolysis. For the small group of patients studied, this author found that antibody production occurred commonly, but no patient experienced detectable levels of hemolysis. 22 Therefore, it is difficult to interpret positive tests and it cannot be recommended that antiglobulin testing be routinely performed for all recipients of minor or bidirectional incompatible HSC components. The clinical staff caring for the patient must be vigilantly aware of the possibility of brisk hemolysis occurring 1 to 3 weeks after transplantation. Special attention must be devoted to the recipient if methotrexate, trimetrexate, mycophenylate mofetil, or other anti-metabolite is not used as part of the GVHD prophylactic regimen and the transplant team must prospectively identify these patients at risk. Transfusion of blood from donors of the recipient blood group should not occur during the transplant course; it is the opinion of this author that this increases the risk of clinically significant hemolysis, although admittedly with few data to support this contention.
Bidirectional red cell incompatibility
The patient undergoing bi-directional red cell-incompatible HSC transplantation must be managed for the immunohematological complications of both major and minor incompatible transplantation. Most red cell depletion techniques also effectively deplete plasma from the HSC component with no additional nucleated cell loss. It is conceivable that both delayed hemolytic transfusion reaction and delayed red cell engraftment may be experienced by these patients.
Transfusion support for red cell-incompatible transplantation
Transfusion support of the red cell-incompatible HSC recipient must consider the immunohematology of both the recipient and the donor. The reports of hemolysis involving non-ABO red cell antigens emphasize the importance of Bone Marrow Transplantation Red cell components should be packed or washed to reduce plasma volume, or components from donors with low isoagglutinin titers. Shown are the first choice for platelet support; platelets from other blood groups can also be infused but should similarly be concentrated to reduce plasma volume.
screening both donor and recipient for the presence of other antibodies and providing appropriate blood component support before and after transplantation. The recipient should not receive incompatible red cells; for red cell-incompatible transplants, red cell compatibility with both the recipient and the donor must be accommodated to avoid both immediate and delayed hemolytic reactions. In general, red cell (or granulocyte) support of the major incompatible recipient should be of recipient type and of the donor type for minor incompatible recipients (Table 2) . For most patients, this translates into using group O red cells. Plasma product support (including platelets) is the opposite, with donor type being used for major incompatible recipients and recipient type for minor incompatible recipients. The transfusion service providing blood components must have a mechanism alerting the laboratory staff to the need to use components that would not be first choice in the nontransplant setting, but which may be critical for the patient undergoing HSC transplantation.
